http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3454892-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3c98f897e481c452123ce0faf827ddb4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c192ed4c2a13e81a9a80a1f9bf1d316a |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55594 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-115 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-115 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-04 |
| filingDate | 2017-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_42998aa8d2fdb3521a049aaff6472914 |
| publicationDate | 2019-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-3454892-A1 |
| titleOfInvention | An immunogenic composition for the treatment of cancer and methods of preparing the same |
| abstract | The present disclosure relates, in some embodiments, to an immunogenic compositions for the treatment of cancer, methods of preparing an immunogenic composition for the treatment of cancer, and methods of treating cancer subjects with an immunogenic composition. Some embodiments of the present disclosure relate to an immunogenic composition operable as a treatment of cancer in a subject having a subject weight, the immunogenic composition including; an immunoactive tissue extract comprising a protein composition, wherein the immunogenic composition has a final concentration of the protein composition of about 6 mg to about 10 mg of the protein composition per kg of the subject weight; an immune response activator comprising a BCG solution, wherein the immunogenic composition has a final concentration of the immune response activator of about 0.525 to about 0.725 mg of the BCG solution per mL of the immunogenic composition; and an immune response mitigator comprising a formaldehyde solution, wherein the immunogenic composition has a final concentration of the formaldehyde solution of about 0.005% to about 0.035%. |
| priorityDate | 2016-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 103.